Salonen J, Purokivi M, Bloigu R, et al, Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases, BMJ Open Respiratory Research 2020;7:e000563. doi: 10.1136/bmjresp-2020-000563
Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases
|Author:||Salonen, Johanna1,2; Purokivi, Minna3; Bloigu, Risto4;|
1Respiratory Medicine, Research Unit of Internal Medicine, University of Oulu, Oulu, Finland
2Medical Research Center, Oulu University Hospital, Oulu, Finland
3The Center of Medicine and Clinical Research, Division of Respiratory Medicine, Kuopio University Hospital, Kuopio, Finland
4Medical Informatics and Statistics Research Group, University of Oulu, Oulu, Finland
|Online Access:||PDF Full Text (PDF, 0.6 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2020062545680
|Publish Date:|| 2020-06-25
Background: The aim of this study was to compare the clinical characteristics, causes of death and factors impacting on the prognosis of patients with idiopathic pulmonary fibrosis (IPF) and other fibrosing interstitial lung disease (FILD) with a history of acute exacerbation (AE) of IPF or FILD.
Methods: Retrospective data of hospital treatment periods caused by AE-IPF and AE-FILD were collected from medical records. Clinical features and survival data of IPF and non-IPF cases were evaluated and compared. The underlying and immediate causes of death were gathered from death certificates.
Results: A total of 128 patients fulfilled the criteria for inclusion. IPF (n=79/62%), rheumatoid arthritis-associated interstitial lung disease (RA-ILD; n=17/14%) and asbestosis (n=11/8.6%) were the most common FILD subgroups in the study. The median survival after hospitalisation in AE-IPF was 2.6 months compared with 21 months in other AE-FILDs (p<0.001). The survival difference was not explained by age, gender or pulmonary function test results at the time of hospitalisation. Patients with non-specific interstitial pneumonia and RA-ILD had the most favourable prognosis. ILD was the most common underlying cause of death in both patients with IPF and with other FILD accounting for 87% and 78% of deaths, respectively.
Conclusions: We detected a significantly longer survival in AE of patients with non-IPF compared with that of AE-IPFs. The prognosis of patients was affected by the underlying lung disease since pulmonary fibrosis was the underlying cause of death in the majority of all patients with FILD having experienced an AE.
BMJ open respiratory research
|Article number:||UNSP e000563|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
JS has received personal grants for scientific work from Foundation of the Finnish Anti-Tuberculosis Association and the Research Foundation of the Pulmonary Diseases HES. RK has received grants for the study group from Foundation of the Finnish Anti-Tuberculosis Association, the Research Foundation of the Pulmonary Diseases, Jalmari and Rauha Ahokas Foundation and the Research Foundation of North Finland.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ